Our report on Ceapro Inc. is updated and continues to be rated Speculative Buy. Earnings are down in the first half of 2021 but this is due to increased spending on its Phase 1 (safety) trial of its Beta Glucan pills. The company is generating ample cashflow and has virtually no debt. The hope if that some of its research efforts will payoff which could potentially be quite lucrative. But this remains a speculative investment.